[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coagulation-factor-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coagulation-factor-deficiency":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100553123","phase-4-swift---swiss-factor-xiii-trial-in-pph-100553123",false,"NCT06481995","SWIFT - SWIss Factor XIII Trial in PPH","Early Factor XIII Replacement in Postpartum Hemorrhage: Multi-center, Randomized, Controlled, Investigator-initiated Trial","SWIFT","Inclusion Criteria:\n\n* planned vaginal delivery\n* singleton vital pregnancy\n* gestational age at delivery \\>= 30+0 weeks\n* maternal weight at admission for delivery \\\u003C100 kg\n\nExclusion Criteria:\n\n* Antithrombotic therapy in pregnancy (therapeutic dosage) until admission for delivery (LMWH, UFH)\n* diagnosis of preeclampsia (ISSHP classification , eclampsia or HELLP syndrome),\n* known history of deep vein thrombosis or pulmonary embolism,\n* known diagnosis of bleeding disorder or thrombophilia,\n* known thrombocytopenia during second half of pregnancy with thrombocytes \\\u003C 100 G\u002FL,\n* known anemia during second half of pregnancy with Hb\\\u003C80 g\u002FL,\n* known sickle cell disease,\n* known malignant tumor(s),\n* participation in another study with investigational drug within the 30 days preceding and during the present study,\n* inability to follow the procedures of the study, e.g. due to language problems,\n* known or suspected non-compliance, drug or alcohol abuse.\n\nExclusion criteria prior randomization\n\n* Maternal fever ≥39.0°C\n* unplanned cesarean delivery is performed,\n* Measured Blood Loss remains \\\u003C 700 mL after administration of 1g tranexamic acid .\n* Postpartum hemorrhage due to occult bleeding (intra-abdominal, retroperitoneal, parametric),","FEMALE","18 Years",{"count":20,"type":21},988,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).\n\nSummary of current body of evidence:\n\n* Morbidity and mortality due to PPH is rising.\n* Current guidelines focus on replenishment of fibrinogen as an initial step in the treatment of PPH-related coagulopathy, despite non-conclusive evidence in all prospective trials.\n* Trials from other specialties demonstrate a significant impact of FXIII on perioperative bleeding complications; a previous study at the University Hospital Zurich showed that pre-partum factor XIII activity had a strong association to postpartum blood loss.\n\nTherefore, this nationwide, multi-center, randomized, controlled trial in multiple perinatal centers across Switzerland will be conducted. The goal is to determine if postpartum blood loss and PPH-related complications can be reduced by replenishing FXIII.\n\nAll participating women receive, according to the national guideline, 1g tranexamic acid (TXA) i.v. in case of PPH (measured blood loss \\[MBL\\] ≥ 500 mL) during the pre-study phase. Randomization takes place if bleeding continues and exceeds 700mL. The intervention group then receives FXIII (Fibrogammin®) according to approved dosage in addition to obstetric standard of care treatment for causes of PPH; the control group receives only standard of care treatment.",[27,28,29,30,31],"Postpartum Hemorrhage","Coagulation Disorder","Coagulation Factor Deficiency","Hemorrhage","Postpartum Complication",[33,34],"Postpartum hemorrhage","coagulation factor XIII","RECRUITING","2026-04-21",{"date":38,"type":39},"2026-04-27","ACTUAL",{"date":41,"type":39},"2024-07-09",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Christian Haslinger","OTHER",9,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":77,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008","NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",true,"ALL",{"count":57,"type":21},3000,"5 Years","OBSERVATIONAL","This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[62,63,64,65,66,67,68,69,29,70,71,72,73,74,75,76],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Disseminated Intravascular Coagulation","Thrombophilia","Deep Vein Thrombosis","Pulmonary Embolism","Thrombotic Microangiopathies","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Platelet Dysfunction","Arterial Thromboembolism","Bleeding Disorder","Thrombosis",[76,78],"Hemostasis","2024-12-05",{"date":81,"type":39},"2024-12-11",{"date":83,"type":39},"2024-11-01",{"date":85,"type":21},"2030-12-31",{"name":87,"class":46},"Peking University People's Hospital",5]